Clinical trials: sponsored by British Columbia Cancer Agency
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives…
- Trial name
- PROTRACT (NCT04015622)
- Testing
- Enzalutamide, Docetaxel
- Where
- 7 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Cancer
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring…
- Trial name
- PREDiCTc (NCT04814095)
- Testing
- QOL, CT imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Cancer
PRecision Oncology Evidence Development in Cancer Treatment - Liquid
The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in…
- Trial name
- PREDiCTl (NCT05057234)
- Testing
- FoundationOne liquid CDx, Quality of life questionnaires
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- British Columbia Cancer Agency
EGFR Activating Mutation, Leptomeningeal Metastasis
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life.
- Conditions
- EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer
- Trial name
- NCT05257967
- Testing
- Lumbar puncture and Phlebotomy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Cancer
Evidence Development in Cancer Treatment - Real World: PREDiCTrw
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with therapy that has preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost…
- Trial name
- NCT06242912
- Testing
- QOL - quality of life, Radiographic or laboratory evaluation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Orbital Lymphoma
Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma
Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities.
- Trial name
- NCT07210749
- Testing
- External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received…
- Conditions
- Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
- Trial name
- NCT07299409
- Testing
- Sacituzumab Govitecan (SG)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nathalie Levasseur
Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin…
- Conditions
- Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
- Trial name
- NET-COMPARE (NCT07621146)
- Testing
- 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Acute Myeloid Leukemia, AML With FLT3 Mutation
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
The goal of this clinical trial is to learn if gilteritinib-azacitidine-venetoclax combination drug therapy works to treat adults with FLT3-wt acute myeloid leukemia (AML).
- Trial name
- GAVE001 (NCT07755202)
- Testing
- gilteritinib-azacitidine-venetoclax
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Florian Kuchenbauer
Advanced Bladder Cancer
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs enfortumab vedotin and pembrolizumab (EV/P) works to treat adults with advanced bladder cancer.
- Trial name
- Chrono-EVP (NCT07346053)
- Testing
- enfortumab vedotin and pembrolizumab (EV/P)
- Where
- 5 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Guliz Ozgun
Prostate Neoplasm
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).
- Trial name
- NCT01630967
- Testing
- Degarelix
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Diffuse Large B-cell Lymphoma, Multiple Myeloma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor…
- Conditions
- Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06224309
- Testing
- 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Tumors
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
- Trial name
- NCT02933242
- Testing
- Stereotactic Ablative Body Radiotherapy
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- British Columbia Cancer Agency
Advanced Kidney Cancer
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs nivolumab/ipilimumab (ICI/ICI) works to treat adults with advanced kidney cancer.
- Trial name
- NCT07338981
- Testing
- Nivolumab & Ipilimumab, Nivolumab + Ipilimumab
- Where
- Canada
- Volunteers
- 142 people
- Sponsor
- Guliz Ozgun
Multiple Cancers, Multiple Indications Cancer
HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG
Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG.
- Conditions
- Multiple Cancers, Multiple Indications Cancer, Feasibility Studies
- Trial name
- HELP (NCT07295171)
- Testing
- Oral FDG scan
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- British Columbia Cancer Agency
Colorectal Cancer, Colorectal Cancer Metastatic
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
- Trial name
- COMPARISON (NCT03364621)
- Where
- 2 sites in Canada
- Volunteers
- 17 people
- Sponsor
- University Health Network, Toronto
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
Brain Metastases, Adult
RAPid SimPLE Targeted Radiation Treatment for Brain Metastases
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
- Trial name
- RAPPLE (NCT05050929)
- Testing
- Targeting All Brain Metastases
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency